Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial |
Aug 2020 |
Lancet Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
Jun 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
Jun 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
Jul 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
Jul 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial |
Jan 2024 |
Lancet |
Myelodysplastic Syndromes (MDS) |
Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review |
Jan 2024 |
Journal of Women's Health |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes |
Aug 2020 |
Journal of Patient-Reported Outcomes |
Myelodysplastic Syndromes (MDS) |
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs |
Dec 2020 |
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease |
Dec 2020 |
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |